Bacterial isolates obtained from swine with various clinical diseases were tested for susceptibility to tilmicosin by minimum inhibitory concentration (MIC) and Kirby-Bauer disk diffusion tests using National Committee on Clinical Laboratory Standards methodology. The tilmicosin MIC 90 was Յ0.125 g/ml for Erysiopelothrix rhusiopathiae, Յ1 g/ml for Haemophilus parasuis isolates, 8 g/ml for Actinobacillus suis and Pasteurella multocida type A, 16 g/ml for toxigenic and nontoxigenic P. multocida type D, 64 g/ml for Bordetella bronchiseptica, and Ͼ128 g/ml for Staphylococcus hyicus and Streptococcus suis. The results of disk diffusion testing matched well with the MIC results for each pathogen. This in vitro survey of tilmicosin activity against various swine isolates suggests that further clinical evaluation of tilmicosin in swine may be warranted for disease associated with E. rhusiopathiae, H. parasuis, and A. suis but not B. bronchiseptica, S. suis, or S. hyicus.
Porcine respiratory disease complex (PRDC) is characterized as a general pneumonic condition having a multifactorial etiology. Mycoplasma infection and viral infections such as porcine reproductive and respiratory syndrome (PRRS), swine influenza, and pseudorabies allow for opportunistic bacteria to colonize and infect the lung and subsequently contribute to pneumonic conditions. Several bacterial agents, including Pasteurella multocida, Actinobacillus pleuropneumoniae, Streptococcus suis, Bordetella bronchiseptica, Actinobacillus suis, Erysipelothrix rhusiopathiae, and Haemophilus parasuis have been isolated from pneumonic lungs in swine. 14 Additionally, particularly in high-health status herds, S. suis, A. suis, E. rhusiopathiae, S. hyicus, and H. parasuis are associated with a wide range of systemic clinical conditions such as endocarditis, pericarditis, meningitis, polyserositis, and septicemia. 6 Tilmicosin is a semisynthetic macrolide antibiotic used exclusively in veterinary medicine. It is currently approved for control of swine and bovine respiratory disease. 7, 8 Tilmicosin has activity against Gram-negative bacteria associated with respiratory disease such as P. multocida, Mannheimia (Pasteurella) haemolytica, and A. pleuropneumoniae in addition to mycoplasma. 4, 5, 11, 12 Swine respiratory disease associated with A. pleuropneumoniae and P. multocida has been successfully controlled by tilmicosin incorporated into the feed ration at a dose range of 200-400 ppm 1, 8, 9 (Walters J, Brown DR, Tarrant ME: 1994, Efficacy of Pulmotil (tilmicosin in premix form) against naturally occurring pneumonia in growing fattening pigs. In: 6th International Congress of the European Association for Veterinary Pharmacology and Toxicology, Abstract 09, Edinburgh, UK). However, little is known about its activity against other bacterial pathogens of swine. The objective of the present survey was to determine tilmicosin susceptibility of several porcine pathogens by minimal inhibitory concentration (MIC) and Kirby-Bauer (KB) disk diffusion. Acceptable in vitro activity of tilmicosin against other economically important porcine respiratory pathogens may suggest potential future indications for tilmicosin in swine.
Recent clinical isolates (1994) (1995) (1996) (1997) (1998) were collected by Colorado Animal Research Enterprises a from swine diagnosed with clinical disease. The isolates originated from diagnostic laboratories from diverse geographical locations (Pennsylvania, Illinois, Iowa, Kentucky, Oklahoma, South Dakota, Nebraska, Kansas, Colorado). The isolates included 25 A. suis; 50 B. bronchiseptica; 32 E. rhusiopathiae; 50 H. parasuis; 29 P. multocida, type A; 27 P. multocida, type D (nontoxigenic); 6 P. multocida, type D (toxigenic); 9 S. hyicus; and 50 S. suis (mostly type 2). Most of these isolates (80%) were recovered from the respiratory tract, while the remaining isolates were isolated from other organs including skin, spleen, brain, liver, kidney, and heart. These isolates were tested for tilmicosin susceptibility by MIC and KB disk diffusion using National Committee on Clinical Laboratory Standards (NCCLS) methodology. 10 Standard media and testing conditions that provided acceptable growth for H. parasuis and E. rhusiopathiae were determined empirically because NCCLS-recommended methods did not support adequate growth.
Briefly, tilmicosin b was dissolved in 4 ml of 95% ethanol at a concentration of 12,800 g/ml and the volume was adjusted to 10 ml with distilled H 2 O and further diluted in broth to achieve the final concentration. The final tilmicosin concentrations, ranging from 128 g/ml to 0.125 g/ml, were dispensed (100 l) into sterile 96-well, round-bottom microtiter plates. Plates were frozen at Ϫ70 C until needed. Each organism was suspended or grown to approximately a 0.5 McFarland turbidity suspension (ϳ1 ϫ 10 8 CFU/ ml). Five milliliters of the standardized suspension was added to 17.5 ml of sterile water. To each well, 1.5 l of the inoculum was added, resulting in a final concentration of ϳ5 ϫ 10 5 CFU/ml in each well. However, in the case of H. parasuis (0.5 McFarland standard ϳ3 ϫ 10 7 CFU/ml) and E. rhusiopathiae (0.5 McFarland standard ϳ6 ϫ 10 8 CFU/ml), modification of the inoculum preparation was done to account for the difference in CFU/ml obtained with a 0.5 McFarland standard suspension. For H. parasuis, a 0.5-ml aliquot from a 2-ml overnight culture (ϳ24 hours) was used to inoculate 4.5 ml of fresh Mueller-Hinton II broth c supplemented with 15 g/ml hematin, d 15 g/ml ␤-NAD, d and 5 g/liter yeast extract e (MHBS) and grown to 0.5 McFarland turbidity standard. The suspension was added to 10 ml sterile water, and 5 l was used to inoculate wells. For E. rhusiopathiae, 2.5 ml of a 0.5 McFarland turbidity standard was prepared by suspending colonies from blood agar in brain heart infusion broth e (BHI). An aliquot of the suspension (1.5 ml) was added to 25 ml sterile water, and 1.5 l was used to inoculate wells. These modifications allowed the inoculum density to be standardized to approximately 5 ϫ 10 5 CFU/ml, consistent with the target inoculum concentration. Mueller-Hinton II broth was used for all isolates, with the exception of H. parasuis (MHBS) and E. rhusiopathiae (BHI). Plates were incubated aerobically for 16-20 hours at 37 C. Haemophilus parasuis and E. rhusiopathiae required up to 2 days of incubation, and H. parasuis also required 5% CO 2 incubation. The MIC results were interpreted as the lowest concentration of tilmicosin that completely inhibited growth, as detected with the unaided eye.
Disk diffusion susceptibility testing was performed by swabbing an adjusted suspension of each organism onto Mueller-Hinton II agar c (B. bronchiseptica, S. hyicus, and S. suis) or Mueller-Hinton agar plus 5% sheep blood c (A. suis, E. rhusiopathiae, and P. multocida) or Chocolate Mueller-Hinton II agar c (H. parasuis). Slight modifications of the NCCLS inoculum preparation were done for H. parasuis and E. rhusiopathiae to allow for adequate growth. Briefly, a 5-ml 0.5 McFarland turbidity suspension of H. parasuis was pelleted, resuspended in 0.5 ml broth, and used to swab plates (ϳ3 ϫ 10 8 CFU/ml). A 0.5 McFarland suspension of E. rhusiopathiae was diluted 1:4 (ϳ1.7 ϫ 10 8 CFU/ml) and used to swab plates. Tilmicosin disks e containing 15 g of antibiotic were applied to the dried plates, and the plates were incubated under the same conditions as the MIC tests for 16-18 hours, except for H. parasuis and E. rhusiopathiae, which required up to 2 days incubation. Zones of inhibition were measured to the nearest millimeter. The growth conditions, media, and quality-control procedures used to determine the MIC and zone of inhibition for H. parasuis and E. rhusiopathiae will be forwarded to a working group of Veterinary Antimicrobial Susceptibility Testing (V-AST) subcommittee of the NCCLS for consideration as a standard procedure.
Concurrent with the testing of the field isolates, the appropriate quality-control strain, Staphylococcus aureus ATCC 29212, Staphylococcus aureus ATCC 25923, or Actinobacillus pleuropneumoniae ATCC 27090, was tested by MIC and/or disk diffusion. There are currently no testing guidelines for H. parasuis and E. rhusiopathiae. Therefore, for quality assurance, quality-control strains were first tested using the same medium in triplicate on 3 days to establish a range of expected values and then were tested concurrently with H. parasuis and E. rhusiopathiae. The results provided performance monitoring for each test and served to assure that the resulting tilmicosin MIC and zone size values for S. aureus and A. pleuropneumoniae were in compliance. Inoculum preparations were serial diluted and plated to ensure the proper concentration of approximately 5 ϫ 10 5 CFU/ml. Acceptable MIC and KB disk diffusion results for each quality-control strain using different media are summarized in Table 1 . Acceptable NCCLS qualitycontrol ranges were used or were set as one doubling dilution above and below the MIC modal or average zone diameter that was observed during the testing for H. parasuis and E. rhusiopathiae. All quality control strains were within these limits. Tilmicosin MIC range, minimum, maximum, MIC modal , MIC 50 , and MIC 90 for each swine pathogen are summarized in Table 2 . The MIC 90 of tilmicosin was lowest for isolates of E. rhusiopathiae and H. parasuis (MIC 90 Ͻ0.125 g/ml and 1 g/ml, respectively) followed by A. suis; P. multocida, type A (MIC 90 ϭ 8 g/ml); and P. multocida, type D (MIC 90 ϭ 16 g/ml). The highest tilmicosin MIC 90 s (Ͼ64 g/ml) were observed for B. bronchiseptica, S. hyicus, and S. suis. These results agree with a previous study that reported tilmicosin MIC 90 Ͼ64 g/ ml for S. suis and 8 g/ml for P. multocida. 12 The minimum, maximum, and average zone of inhibition diameter for tilmicosin against each swine pathogen is summarized in Table 3 . Average zone of inhibition from highest to lowest was E. rhusiopathiae (36 mm) followed by H. parasuis (22 mm); P. multocida, type A (18 mm); A. suis (15 mm); P. multocida, type D, toxigenic (15 mm); and P. multocida, type D, nontoxigenic (13 mm) . Average zone of inhibition by tilmicosin against B. bronchiseptica, S. hyicus, or S. suis was negligible (0 mm). The MIC values matched well with the KB zones of inhibition for all of the pathogens tested (scattergram data obtained but not shown).
The observation that the most fastidious pathogens were the most sensitive in this study may suggest that the slow growing nature of H. parasuis and E. rhusiopathiae impacted the degree of inhibition. These isolates exhibited tilmicosin MICs much lower and zones of inhibition much greater than other genera. It is conceivable that a bacteriostatic antibiotic such as tilmicosin could inhibit fastidious bacteria in an in vitro system very effectively at the lowest level of antibiotic commonly used in MIC determinations and would not reflect its true sensitivity. However, the disk diffusion 
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No .  %   0  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38 results offer insights into this problem of interpretation. Kirby-Bauer disk diffusion testing reflects a race between bacterial growth and diffusion of tilmicosin from the disk into the agar in addition to the relative susceptibility of the test organism. In this study, H. parasuis and E. rhusiopathiae exhibited poor growth after 18-24 hours; the additional 24-hour incubation allowed even greater diffusion of tilmicosin and thus a larger zone of inhibition because even a very diffuse concentration of tilmicosin was still able to effectively inhibit growth.
Therapeutic outcome, pharmacokinetics, and the minimum inhibitory concentration all contribute to the efficaciousness of an antibiotic. Low MICs do not always predict clinical success; however, high MICs are often predictive of clinical failure. Therefore, tilmicosin would be expected to have little efficacy against swine disease associated with B. bronchiseptica, S. suis, or S. hyicus. For example, one study examining the efficacy of tilmicosin against respiratory disease in swine found little efficacy against respiratory disease associated with S. suis. 2 The pharmacokinetics of tilmicosin have been thoroughly studied in swine. Pigs fed 400 ppm tilmicosin attained a mean peak serum concentration of 0.23 g/ml and exhibited a mean tilmicosin lung concentration of 2.29 g/g between 2 and 4 days postadministration (Stoker J, Parker R, Spencer Y: 1996, The concentration of tilmicosin in pig serum and respiratory tissue following oral administration with Pulmotil via the feed at a level of 400g/ tonne. In: Proceedings of the 14th International Pig Veterinary Society Congress, p. 656, and Thomson TD, Darby JM, Moran JW, Tonkinson LV: 1994, Serum and lung concentration in swine following dosing with tilmicosin fortified feeding. In: Proceedings of the 13th International Pig Veterinary Society Congress, p. 330).
In clinical trials testing tilmicosin efficacy against swine pneumonia, 74.4% of A. pleuropneumoniae isolates and 72.4% of P. multocida isolates had MICs Ն4 g/ml, well above the serum and lung levels, yet excellent efficacy was observed. Several factors offer a mechanism of action that provides an understanding of the observed clinical efficacy. Tilmicosin is known to concentrate within swine phagocytes in vitro and in vivo 13 (Blais J, Chamberland S: 1994, Intracellular accumulation of tilmicosin in primary swine alveolar macrophages. In: Proceedings of the 13th International Pig Veterinary Society Congress, p. 331).
Since leukocytes migrate to the site of infection, intracellular accumulation of tilmicosin within the leukocyte lysosomes offers a unique mechanism of delivering the antibiotic to the site of infection. At the site of infection, intracellular tilmicosin can augment the killing of ingested bacteria within the phagolysosome and some may be effluxed into the local microenvironment. Thus, the concentration of tilmicosin at the foci of infection may be well above the target MIC. Besides its direct antibacterial action, tilmicosin can significantly inhibit bacteria even at subMIC levels and augment host defenses. Tilmicosin has a very strong postantibiotic effect (PAE) on P. multocida, A. pleuropneumoniae, B. bronchiseptica, and P. haemolytica even at 1/8 the MIC. 3 Recent evidence demonstrated that tilmicosin augmented the production of phagocyte lysosomal enzymes, acid phosphatase, lysozyme, and ␤-glucuronidase. 13 The detrimental effects of tilmicosin on bacterial physiology and the beneficial effects on host defenses can facilitate a shift in the struggle between host and pathogen in favor of the host.
This in vitro survey of tilmicosin activity against various swine pathogens suggests that further clinical evaluation of tilmicosin in swine may be warranted for disease associated with E. rhusiopathiae, H. parasuis, and A. suis but not B. bronchiseptica, S. suis, or S. hyicus.
This study also has provided a starting point for a standardized medium and testing conditions for anti-biotic susceptibility testing of E. rhusiopathiae and H. parasuis isolates.
